España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Alto Neuroscience
ANRO
NYSE
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$3.89
0.17
4.57%
At close: -
$3.94
0.05
1.29%
After Hours: Dec 20, 6:56 PM EDT
Get Report
Comment
Alto Neuroscience (ANRO) Forecast
News
Earnings
Alto Neuroscience (ANRO) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Alto Neuroscience (NYSE:ANRO) Stock
Alto Neuroscience Stock (NYSE: ANRO)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, December 16, 2024
This Addus HomeCare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Avi Kapoor
Jones Trading Initiates Coverage On Alto Neur...
Benzinga Newsdesk
Wednesday, December 11, 2024
Alto Neuroscience Highlights Data From Precis...
Benzinga Newsdesk
Wednesday, November 13, 2024
Stifel Maintains Buy on Alto Neuroscience, Lo...
Benzinga Newsdesk
Tuesday, November 12, 2024
Alto Neuroscience Q3 2024 GAAP EPS $(0.62) Be...
Benzinga Newsdesk
Wednesday, October 23, 2024
Nasdaq Down 2%; US Crude Stocks Increase
Avi Kapoor
Neuropsychiatry-Focused Alto Neuroscience's Mid-Stage Depression Trial Disappoints, Analyst Notes Failure Raises Concerns About Platform
Vandana Singh
Gold Moves Lower; AT&T Earnings Top Views
Avi Kapoor
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights
Wedbush Downgrades Alto Neuroscience to Neutr...
Benzinga Newsdesk
Dow Tumbles Over 250 Points; Boeing Posts Q3 Loss
Avi Kapoor
Enphase Energy Posts Downbeat Results, Joins McDonald's, Seagate And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Avi Kapoor
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
Alto Neuroscience shares are trading lower af...
Benzinga Newsdesk
Baird Maintains Outperform on Alto Neuroscien...
Benzinga Newsdesk
Why Stride Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
Tuesday, October 22, 2024
Alto Neuroscience shares are trading lower af...
Benzinga Newsdesk
Alto Neuroscience Announces That The Phase 2b...
Benzinga Newsdesk
Alto Neuroscience Reports Topline Results Fro...
Benzinga Newsdesk
Tuesday, September 10, 2024
Wedbush Reiterates Outperform on Alto Neurosc...
Benzinga Newsdesk
Wednesday, September 04, 2024
Alto Neuroscience Announces Peer-Reviewed Pub...
Benzinga Newsdesk
Tuesday, September 03, 2024
Wedbush Initiates Coverage On Alto Neuroscien...
Benzinga Newsdesk
Tuesday, August 13, 2024
Alto Neuroscience Q2 EPS $(0.60) Beats $(0.63...
Benzinga Newsdesk
Thursday, July 25, 2024
Alto Neuroscience Receives $11.7M Funding Awa...
Benzinga Newsdesk
Tuesday, July 16, 2024
Alto Neuroscience Completes Enrollment In Pha...
Benzinga Newsdesk
Alto Neuroscience Completes Enrollment In ALT...
Benzinga Newsdesk
Friday, June 21, 2024
Rodman & Renshaw Initiates Coverage On Alto N...
Benzinga Newsdesk
Thursday, June 20, 2024
Alto Neuroscience Initiates Phase 2 Study Of ...
Benzinga Newsdesk
Tuesday, May 21, 2024
Alto Neuroscience Names Michael Hanley As COO
Benzinga Newsdesk
Tuesday, May 14, 2024
Alto Neuroscience Q1 2024 GAAP EPS $(0.76) Mi...
Benzinga Newsdesk
Tuesday, April 23, 2024
Treatment Patch For Schizophrenia: Newly Listed Alto Neuroscience Is Uniquely Positioned In Neuropsychiatry Landscape
Vandana Singh
Alto Neuroscience Announces Phase 1 Results F...
Benzinga Newsdesk
Wednesday, April 03, 2024
Alto Neuroscience Has Initiated Phase 2 Study...
Benzinga Newsdesk
Monday, March 25, 2024
Stifel Reiterates Buy on Alto Neuroscience, M...
Benzinga Newsdesk
Thursday, March 21, 2024
Alto Neuroscience FY23 EPS $(9.73) Down From ...
Benzinga Newsdesk
Tuesday, February 27, 2024
Stifel Initiates Coverage On Alto Neuroscienc...
Benzinga Newsdesk
Jefferies Initiates Coverage On Alto Neurosci...
Benzinga Newsdesk
Baird Initiates Coverage On Alto Neuroscience...
Benzinga Newsdesk
Friday, February 02, 2024
Alto Neuroscience Prices Upsized Initial Publ...
Benzinga Newsdesk
Thursday, February 01, 2024
Alto Neuroscience, Inc IPOs Tomorrow, Here's What You Need To Know
Benzinga Insights
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch